Loading…
← CockpitCompetitor Analysis › 1877.HK Shanghai Junshi Biosciences Co., Ltd. Class HOpen in the cockpit ↗

Shanghai Junshi Biosciences Co., Ltd. Class H1877.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

Chinese biopharma known for toripalimab, a PD-1 immuno-oncology antibody approved in China and the US.

≈ A Chinese Bristol Myers Squibb-style oncology immunotherapy developerMomentum weak 22
Mkt cap
$3.49B
US dollars, full cap
Free float
73%
of shares outstanding
$/day
$3.10M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-10.7 pp
WACC 8.6%
Hurdle
n/a
no reverse DCF
Next earnings
134 days
1 Apr 2027
Close · HKDHK$13.92
1D-1.4%
1W-11.2%
1M-16.0%
3M-26.2%
6M-38.4%
YTD-34.8%
1Y-45.2%
ATR %5.3%
52w lowhigh54.8% off high

What Shanghai Junshi Biosciences does

Chinese biopharma known for toripalimab, a PD-1 immuno-oncology antibody approved in China and the US.

Earns from toripalimab sold in China, where national insurance reimbursement widens access at lower prices, and from licence income: Coherus sells it in the US as Loqtorzi and makes upfront and milestone payments to Junshi under a 2021 agreement.

In one line: A Chinese Bristol Myers Squibb-style oncology immunotherapy developer.

Products and services

  • Toripalimab (PD-1 inhibitor)
  • Oncology pipeline (ADCs, bispecifics)
  • VV116 antiviral (in-licensed)

Customers

  • Hospitals/oncologists in China
  • Coherus BioSciences (US commercialization partner)

Where it sits in the supply chain

  • Biotechnology
  • Immuno-oncology antibodies
  • Branded biologics

What could go right

  • US toripalimab sales ramp via Coherus
  • New indication approvals

What could go wrong

  • Heavy R&D losses
  • Competitive PD-1/PD-L1 market

Moat: narrow (IP / patents, regulatory licence). First Chinese-developed PD-1 approved by FDA; patent-protected antibody.

Headquarters: Shanghai, China · Founded: 2012 · Employees: 2,903

Named competitors

Shanghai Junshi Biosciences at a glance

Size Shanghai Junshi Biosciences (1877.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $3.49B, the 306th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$13.92 on 18 Nov 2026.

Performance Over six months the shares fell 38.4%, against +8.1% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — lowest of 20 in its peer set.

Growth Revenue grew 35.8% over the last twelve months (peer median +7.9%); the operating margin is -14.3% (peer median 12.2%).

Valuation It trades at 8.4× enterprise value to sales against a peer median of 3.1× (4th most expensive of 16).

Capital Return on invested capital runs 10.7 points below its cost of capital (8.6% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026Peer median 1111877.HK 60
Six months, rebased to 100: Shanghai Junshi Biosciences against the median of its 20 peers (local-currency closes).

Shanghai Junshi Biosciences financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$3.65BHK$2.70BHK$2.11BHK$1.66BHK$1.69B
Revenue growth—+28%+27%-2%—
Gross profitHK$3.12BHK$1.96BHK$1.42BHK$789MHK$835M
EBITDAn/a-HK$667M-HK$1.09B-HK$2.41B-HK$2.85B
Net income-HK$480M-HK$949M-HK$1.39B-HK$2.52B-HK$2.78B
Free cash flow-HK$848M-HK$1.35B-HK$2.25B-HK$3.02B-HK$2.46B
Capital expenditureHK$901MHK$833MHK$749MHK$920MHK$458M
Total debtHK$7.98BHK$4.61BHK$3.12BHK$1.97BHK$1.48B

Quarterly statements and history in the cockpit →

Shanghai Junshi Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%+40%ARQTACUTAAS002262SFZNWOCKPHARMAAMLXVRDN2096PPLPHARMA600521000739OGNSLSXENE15131877.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Shanghai Junshi Biosciences is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×50×100×ARQTACUTAAS002262SFZNWOCKPHARMAVRDN2096000739TARS1877.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai Junshi Biosciences is the large dot.

Shanghai Junshi Biosciences competitors and peer comparison

Head to head with its named competitors (1877.HK vs 1801.HK vs 9926.HK vs BMY)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Shanghai Junshi Biosciences 1877.HK$3.49B-38%+36%-14%8.4×n/a
Innovent Biologics 1801.HK$18.9B+4%+43%17%7.3×11.6%
Akeso 9926.HK$7.01B-48%+42%-25%12.9×n/a
Bristol Myers Squibb BMY$122B+3%+4%33%3.1×-13.1%

How Shanghai Junshi Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai Junshi Biosciences against its 20 peers (data as of 18 Nov 2026)
Measure1877.HKPeer medianRank in peer set
1-month return-16.0%+4.5%lowest of 21
6-month return-38.4%+8.1%lowest of 20
Distance from 52-week high-54.8%-18.8%lowest of 21
Revenue growth (TTM)+35.8%+7.9%5th highest of 18
Operating margin-14.3%12.2%2nd lowest of 16
EV / Sales8.4×3.1×4th most expensive of 16
ROIC minus cost of capital-10.7 pp+4.3 pp5th lowest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Shanghai Junshi Biosciences 1877.HKHong Kong$3.49B-38%+36%-14%8.4×n/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%6.6×49.2%+367.3%
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%20.4×n/an/a
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%3.1×-2.1%+12.0%
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%2.8×n/an/a
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%9.3×58.0%+4.2%
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%106.6×n/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%2.6×-3.4%+10.6%
Piramal Pharma PPLPHARMA.NSIndia$3.40B+38%+9%3%3.8×n/an/a
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%0.6×-4.9%+7.8%
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%3.2×6.4%+5.9%
Apeloa Pharmaceutical 000739.SZChina$3.37B+17%-16%10%2.5×4.7%+4.5%
Organon & OGNUnited States$3.66B+3%-3%20%1.8×-4.1%-1.0%
Viking Therapeutics VKTXUnited States$3.34B-9%n/an/an/an/an/a
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
Livzon Pharmaceutical 1513.HKHong Kong$3.73B-9%-10%19%2.3×-7.0%+2.0%
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%5.2×34.7%+159.5%
China National Medicines 600511.SSChina$3.26B+3%+3%4%0.3×-10.0%+5.4%

Questions

Who are Shanghai Junshi Biosciences's main competitors?
Named competitors: BeiGene (private or unlisted), Innovent Biologics (1801.HK), Akeso (9926.HK), Bristol Myers Squibb (BMY). The cockpit's measured peer set (industry) also includes Arcutis Biotherapeutics (ARQT), Acutaas Chemicals (ACUTAAS.NS), Jiangsu Nhwa Pharmaceutical (002262.SZ), Siegfried (SFZN.SW), Parabilis Medicines (PBLS), Wockhardt (WOCKPHARMA.NS).
Is Shanghai Junshi Biosciences expensive compared with its peers?
On ev / sales it trades at 8.4× against a peer median of 3.1×, 4th most expensive of 16 in its peer set.
How has Shanghai Junshi Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned -38.4% against +8.1% for the median peer; over one year -45.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.